Gerald Batist, MD, FACP

Gerald Batist is Chairman of the Department of Oncology, McGill University and is based at the Jewish General Hospital. He is also Director of the McGill Centre for Translational Research in Cancer, which was established to stimulate rapid translation of new discoveries in the research laboratory into clinical benefits for patients and is Principal Investigator for human clinical trials being conducted by Realist. He has an MD from McGill University.

Jim Breitmeyer, MD, PhD

Jim Breitmeyer is the CEO of Oncternal Therapeutics, a clinical-stage oncology company. Prior to this, he was President of Bavarian Nordic Inc. in the US & Executive Vice President of Bavarian A/S, headquartered in Denmark. He is on the Board of Directors of Zogenix, Inc. and until 2012 was Executive Vice President of Development and Chief Medical Officer of Cadence Pharmaceuticals Inc. Jim was Chief Medical Officer of Applied Molecular Evolution Inc., a wholly-owned subsidiary of Eli Lilly and Co. He also served as the President and CEO of the Harvard Clinical Research Institute. Jim also held a variety of positions at Serono Laboratories Inc. Prior to Serono, he served as a founding collaborator and scientific advisor to Immunogen Inc., and held clinical and teaching positions at the Dana Farber Cancer Institute and Harvard Medical School. Jim has a BA in Chemistry from the University of California, Santa Cruz and a M.D. and Ph.D. from Washington University School of Medicine, and is Board Certified in Internal Medicine & Oncology.

David Ettinger, MD, FACP, FCCP

David Ettinger is the Alex Grass Professor of Oncology at the Johns Hopkins University School of Medicine in Baltimore.  He is also professor of medicine, otolaryngology, head and neck surgery, gynecology and obstetrics, and radiation oncology and molecular radiation sciences.  David is member of the board of directors of the National Comprehensive Cancer Network (NCCN) and of the NCCN Guidelines Steering Committee. In addition, he has been chairman of the NCCN non-small cell lung cancer practice guidelines panel, antiemetic practice guidelines panel, & occult primary tumor practice guidelines panel.

Jim Mulé, PhD

Jim Mulé is the Director of Cell-Based Therapies and the Associate Center Director for Translational Research at the H. Lee Moffitt Comprehensive Cancer Center in Tampa, Florida.  Jim is also a Senior Member of both the Immunology and Cutaneous Oncology Programs, as well as an Endowed Chair in Melanoma Research and Treatment.  He also currently holds positions at the National Cancer Institute and the FDA. He has a research focus in the areas of cancer vaccines and cancer immunotherapy.

Donald (Skip) Trump, MD, FACP

Skip Trump has more than 20 years of leadership experience with prestigious cancer care, research and education programs.  He is based at the Inova Schar Cancer Institute in Virginia.  He is also the CEO and Executive Director of Inova and was CEO of Roswell Park Cancer Institute in Buffalo, NY, from 2007-2015, and Associate Institute Director and Senior Vice President for clinical investigations from 2002 to 2007.


Jonathan Bramson, PhD

Jonathan Bramson is a Professor, Department of Pathology & Molecular Medicine.  He is also Associate Dean of Research, Health Sciences, McMaster University, as well as Canada Research Chair in Translational Cancer Immunology.  Jonathan’s research focuses on T cells for cancer immunotherapy. He has established world class GMP and GLP facilities at McMaster for clinical trials of novel cancer immunotherapies.

David Burt, PhD

David Burt has over 25 years in the vaccine industry including as former Director of R&D, GSK Biologicals (North America).  He was also Vice-President, Research at ID Biomedical Corporation, Vice-President, Research for Intellivax International, and Section Head Immunology at Sanofi-Pasteur.

Marc Lussier, PhD

Marc Lussier provides advisory services to biopharma and cell therapy companies. He has extensive experience in cell therapy manufacturing and, in this context, was a major architect of Centre of Excellence for Cellular Therapy (CETC) in Montreal. He previously founded a number of biopharma companies, and is currently Executive Director of Genome Canada's Personalized Cancer ImmunoTherapy Program and COO at SpecificiT Pharma.

Wilson Miller, MD, PhD

Wilson Miller is Director of Laboratory Research, Division of Hematology-Oncology, Department of Medicine, Jewish General Hospital.  He is also Professor, Departments of Medicine and Oncology, McGill University; Director, Clinical Research Unit, Jewish General Hospital; Co-Director, Clinical Research Program, Department of Oncology, McGill University; Director, Developmental Therapeutics Program, Department of Oncology, McGill University; Research Focus: Acute Promyelocytic Leukemia; Breast cancer; Drug development in oncology.

Warren Wakarchuk, PhD

Warren Wakarchuk is Chair at the Department of Chemistry and Biology at Ryerson University, Toronto.  His main research interest is the study of the structure and function of the enzymes involved in producing and degrading various glycoconjugates.  Warrant is a key advisor of Realist for the manufacturing of its glycomimetic products.

J.C. Zúñiga-Pflücker, PhD

J.C. Zúñiga-Pflücker is Professor & Chair, Dept. of Immunology, University of Toronto.  He is also Canada Research Chair in Developmental Immunology, and Senior Scientist, Biological Sciences, Sunnybrook Research Institute and President, Canadian Society for Immunology.